The FDA has accepted for review the resubmitted New Drug Application (NDA) for apomorphine sublingual film (APL-130277; Sunovion) for the treatment of OFF episodes in patients with Parkinson disease (PD).
Exposure to certain types of oral antibiotics may be associated with an elevated risk for Parkinson disease.
The FDA has granted Breakthrough Device designation to the RightEye Vision System, a device that measures and analyzes involuntary eye movements to aid in the assessment of Parkinson disease.
Sunovion has resubmitted the NDA for apomorphine sublingual film for the treatment of OFF episodes experienced by patients with Parkinson disease.
Transcranial magnetic resonance-guided focused ultrasound (tcMRgFUS) thalamotomy shows continued benefit for suppression of medication-refractory essential tremor (ET) at three years.
The Movement Disorder Society Task Force recently published a proposal for new diagnostic criteria for 3 Huntington disease categories.
Patients with Parkinson disease (PD) who use inappropriate antipsychotics may be at an increased risk for pneumonia compared with patients with PD who use more appropriate atypical antipsychotics.
Compared with the general population, patients with bipolar disorder (BD) have an increased risk of developing idiopathic Parkinson disease (PD), study results published in JAMA Neurology suggest. Published studies that included data on the risk for PD in patients with BD vs the general population without BD were included in a systematic review. A total…
Nourianz is now available as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
Elevated plasma neurofilament light chain (NfL) levels are associated with higher disease severity and dementia in patients with Parkinson disease.
